1,594
Participants
Start Date
January 19, 2023
Primary Completion Date
March 6, 2024
Study Completion Date
September 26, 2025
Pembrolizumab/Vibostolimab
Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations
Pembrolizumab
Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations
CHUV (centre hospitalier universitaire vaudois) ( Site 1304), Lausanne
Medizinische Universität Wien-Department of Dermatology ( Site 0600), Vienna
Cliniques universitaires Saint-Luc ( Site 0652), Brussels
Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 1307), Geneva
Hôpital de Sion ( Site 1305), Sion
Melanoma Institute Australia-Clinical Trials Unit ( Site 1450), Wollstonecraft
Blacktown Hospital-Blacktown Cancer and Haematology Centre - Medical Oncology ( Site 1464), Blacktown
Medical Oncology Centre of Rosebank ( Site 1160), Johannesburg
Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 1151), Sandton
Calvary Mater Newcastle-Medical Oncology ( Site 1462), Waratah
GZA Ziekenhuizen campus Sint-Augustinus ( Site 0655), Wilrijk
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 1455), Melbourne
UZ Leuven-General Medical Oncology ( Site 0650), Leuven
Inselspital Bern ( Site 1301), Bern
Universitätsklinikum St. Pölten-Department of Dermatology ( Site 0606), Sankt Pölten
Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 1501), Tauranga
Jessa Ziekenhuis ( Site 0656), Hasselt
Abraham Oncology ( Site 1150), Richards Bay
Ordensklinikum Linz GmbH Elisabethinen-Dermatologie ( Site 0602), Linz
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si, Brisbane
University Hospital Basel ( Site 1303), Basel
The Oncology Centre ( Site 1157), Durban
Gallipoli Medical Research Ltd-GMRF CTU ( Site 1451), Greenslopes
Tasman Oncology Research ( Site 1456), Southport
P3 Research - Palmerston North ( Site 1510), Palmerston North
Cairns Hospital-Clinical Research Unit ( Site 1458), Cairns
Royal Adelaide Hospital-RAH Cancer Centre ( Site 1457), Adelaide
Uniklinikum Salzburg-Department of Dermatology and Allergology ( Site 0604), Salzburg
Université Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 0653), Yvoir
One Clinical Research ( Site 1460), Nedlands
Medizinische Universitaet Innsbruck-Univ Klinik für Dermatologie, Venerologie und Allergologie ( Sit, Innsbruck
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 1161), Port Elizabeth
Ospedale Regionale Bellinzona e Valli ( Site 1308), Bellinzona
Icon Cancer Centre Hobart ( Site 1465), Hobart
Cape Town Oncology Trials ( Site 1155), Cape Town
Cancercare Rondebosch Oncology-Clinical trials ( Site 1159), Rondebosch
New Zealand Clinical Research (Christchurch) ( Site 1509), Christchurch
Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 0601), Graz
UniversitätsSpital Zürich-Dermatology ( Site 1300), Zürich Flughafen
Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 1306), Sankt Gallen
Dunedin Hospital ( Site 1511), Dunedin
Laura and Isaac Perlmutter Cancer Center-Hematology and Oncology ( Site 0113), New York
Icahn School of Medicine at Mount Sinai ( Site 0118), New York
Weill Cornell Medical College ( Site 0115), New York
Charité Universitaetsmedizin Berlin - Campus Mitte-Hauttumorcentrum Charité (HTCC) ( Site 0756), Berlin
R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0132), Lake Success
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0146), Mineola
Assistance Publique Hôpitaux de Marseille - Hôpital de la Ti-Service de Dermatologie et Cancérologi, Marseille
Children's Hospital of Pittsburgh ( Site 0141), Pittsburgh
UPMC Hillman Cancer Center ( Site 0135), Pittsburgh
Georgetown University Medical Center ( Site 0144), Washington D.C.
Onkologikoa - Instituto Oncologico de San Sebastian ( Site 1203), Doniostia - San Sebastian
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1000), Milan
Istituto Europeo di Oncologia IRCCS ( Site 1008), Milan
Universitaetsklinikum Hamburg-Eppendorf ( Site 0752), Hamburg
Elbe Kliniken Stade-Buxtehude, Klinikum Buxtehude-Dermatologisches Zentrum ( Site 0754), Buxtehude
Inova Schar Cancer Institute ( Site 0103), Fairfax
Universitaetsklinikum Schleswig-Holstein Campus Kiel-Hautklinik ( Site 0767), Kiel
Centre Hospitalier de Valence-Service de Dermatologie ( Site 0702), Valence
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1204), Madrid
Levine Cancer Institute ( Site 0138), Charlotte
H.R.U Málaga - Hospital General-Oncology ( Site 1201), Málaga
Medizinische Hochschule Hannover ( Site 0758), Hanover
Johannes Wesling Klinikum Minden-Skin Cancer Center Minden ( Site 0759), Minden
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0110), Miami
Mersin Sehir Eğitim ve Araştırma Hastanesi-Oncology ( Site 1361), Mersin
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 0124), Tampa
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1358), Istanbul
Vanderbilt University Medical Center ( Site 0139), Nashville
St. Jude Children's Research Hospital ( Site 0106), Memphis
The West Clinic, PLLC dba West Cancer Center ( Site 0119), Germantown
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1205), Seville
Azienda Ospedaliero Universitaria ( Site 1002), Modena
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu-Onco-Dermatology ( Site 0707), Nantes
Institut de Cancérologie de l'Ouest-Oncologie Médicale ( Site 0706), Saint-Herblain
Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 0761), Essen
Hospital General Universitario de Valencia ( Site 1200), Valencia
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1004), Meldola
Henry Ford Hospital ( Site 0133), Detroit
University of Iowa-Holden Comprehensive Cancer Center ( Site 0107), Iowa City
Azienda Ospedaliero Universitaria Senese ( Site 1005), Siena
University of Wisconsin Hospital and Clinics ( Site 0108), Madison
Ondokuz Mayıs Universitesi-Oncology department ( Site 1359), Samsun
Sanford Cancer Center ( Site 0125), Sioux Falls
Sanford Fargo Medical Center ( Site 0127), Fargo
Hopital Claude Huriez - CHU de Lille-Clinique de Dermatologie ( Site 0700), Lille
Advocate Medical Group-Oncology ( Site 0102), Park Ridge
Northwestern Memorial Hospital ( Site 0109), Chicago
Centre Hospitalier de Pau ( Site 0708), Pau
Universitätsmedizin Mannheim ( Site 0751), Mannheim
Universitaetsklinikum Heidelberg ( Site 0765), Heidelberg
centre hospitalier lyon sud-Service de dermatologie ( Site 0714), Pierre-Bénite
Instituto Tumori Giovanni Paolo II ( Site 1003), Bari
Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0711), Paris
University of Texas MD Anderson Cancer Center ( Site 0145), Houston
The Melanoma & Skin Cancer Institute ( Site 0120), Englewood
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1001), Napoli
Klinik und Poliklinik für Dermatologie und Allergologie-Dermato-oncology ( Site 0757), München
Comprehensive Cancer Centers of Nevada ( Site 0142), Las Vegas
The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123), Los Angeles
UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0131), Los Angeles
A.O.U. Policlinico Paolo Giaccone-Depatment of Discipline Chirurgiche, Oncologiche e Stomatologiche, Palermo
Universitaetsklinikum Erlangen-Hautklinik ( Site 0750), Erlangen
California Pacific Medical Center - Pacific Campus ( Site 0111), San Francisco
UCSF Medical Center at Mission Bay ( Site 0130), San Francisco
Gustave Roussy-Dermatologie ( Site 0713), Villejuif
Beijing Ji Shui Tan Hospital ( Site 1657), Beijing
Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 1650), Beijing
All India Institute of Medical Sciences-Medical oncology ( Site 1552), New Delhi
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0358), Bogotá
Artemis hospital ( Site 1551), Gurugram
The First Hospital of Jilin University-Oncology ( Site 1665), Changchun
Fudan University Shanghai Cancer Center ( Site 1658), Shanghai
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology (, Nanjing
Jiangsu Province Hospital-Oncology Department ( Site 1663), Nanjing
Zhejiang Cancer Hospital-Oncology ( Site 1661), Hangzhou
The First Affiliated Hospital of Nanchang University ( Site 1652), Nanchang
Fujian Provincial Cancer Hospital ( Site 1659), Fuzhou
Tata Memorial Hospital-Medical Oncology ( Site 1550), Mumbai
Chongqing University Cancer Hospital ( Site 1651), Chongqing
The Second Xiangya Hospital of Central South University-Oncology ( Site 1673), Changsha
Wuhan Union Hospital Cancer Center-Cancer Center ( Site 1664), Wuhan
The Third Hospital of Zhengzhou-Oncology ( Site 1653), Zhengzhou
Sun Yat-sen University Cancer Center-melanoma ( Site 1655), Guangzhou
Guangxi Medical University Affiliated Tumor Hospital ( Site 1668), Nanning
West China Hospital, Sichuan University-Head and Neck Oncology ( Site 1667), Chengdu
Yunnan Province Cancer Hospital-Biotherapy Center ( Site 1666), Kunming
Mediservis del Tolima IPS S.A.S ( Site 0357), Ibagué
Fundación Valle del Lili ( Site 0352), Santiago de Cali
Xinjiang Medical University Cancer Hospital - Urumqi-Bone and Soft Tissue Department ( Site 1674), Ürümqi
Bradford Hill Norte ( Site 0308), Antofagasta
Emek Medical Center-oncology ( Site 0952), Afula
ONCOCENTRO APYS-ACEREY ( Site 0300), Viña del Mar
Rambam Health Care Campus-Oncology Division ( Site 0955), Haifa
Rabin Medical Center-Oncology ( Site 0954), Petah Tikva
Oncocentro Valdivia ( Site 0307), Valdivia
Sheba Medical Center-ONCOLOGY ( Site 0950), Ramat Gan
FALP-UIDO ( Site 0303), Santiago
Oncovida ( Site 0304), Santiago
Clínica UC San Carlos de Apoquindo ( Site 0305), Santiago
Soroka Medical Center ( Site 0953), Beersheba
Bradfordhill-Clinical Area ( Site 0302), Santiago
Hadassah Medical Center ( Site 0951), Jerusalem
Centro Avançado de Tratamento Oncológico- CENANTRON ( Site 0256), Belo Horizonte
ANIMI - Unidade de Tratamento Oncologico ( Site 0255), Lages
Moores Cancer Center ( Site 0116), La Jolla
Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0204), Ciudad Autónoma de Buenos Aires
Instituto Alexander Fleming-Alexander Fleming ( Site 0209), Ciudad Autónoma de Buenos Aires
Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0200), Buenos Aires
Instituto de Oncología de Rosario ( Site 0206), Rosario
Sanatorio Finochietto ( Site 0212), Buenos Aires
Clinica Adventista Belgrano-Oncology ( Site 0211), CABA
VITAZ-Medical Oncology ( Site 0654), Sint-Niklaas
Hospital de Cancer de Londrina-Clinical Research Unit ( Site 0252), Londrina
Associação Hospitalar Beneficente São Vicente de Paulo-Instituto do Câncer ( Site 0259), Passo Fundo
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia ( Site 0262), Santo André
A. C. Camargo Cancer Center ( Site 0258), São Paulo
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0004), Ottawa
Sunnybrook Research Institute ( Site 0003), Toronto
Princess Margaret Cancer Centre ( Site 0006), Toronto
Fourth Hospital of Hebei Medical University ( Site 1669), Shijiazhuang
Shanxi Bethune Hospital ( Site 1660), Taiyuan
Tianjin Medical University Cancer Institute & Hospital-Biotherapy ( Site 1671), Tianjin
Instituto de Cancerología ( Site 0356), Medellín
Fundación Colombiana de Cancerología Clínica Vida ( Site 0355), Medellín
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Dermatologie ( Site 0766), Dresden
Universitätsklinikum Leipzig ( Site 0762), Leipzig
St. James's Hospital-Cancer clinical trials office ( Site 0900), Dublin
Beaumont Hospital, Dublin-Cancer Clinical Trials & Research Unit ( Site 0902), Dublin
AO Santa Maria della Misericordia ( Site 1006), Perugia
Nagoya University Hospital ( Site 1753), Nagoya
Sapporo Medical University Hospital ( Site 1755), Sapporo
Niigata Cancer Center Hospital ( Site 1751), Niigata
Shizuoka Cancer Center ( Site 1752), Nagaizumi-cho,Sunto-gun
National Cancer Center Hospital ( Site 1750), Chuo-ku
Osaka International Cancer Institute ( Site 1754), Osaka
Harbour Cancer & Wellness ( Site 1508), Auckland
Szpital Kliniczny im. H. Swiecickiego nr 2-Oddział Kliniczny Onkologii Klinicznej i Doświadczalnej (, Poznan
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1061), Bydgoszcz
Pratia MCM Krakow ( Site 1053), Krakow
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1058), Siedlce
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warsaw
Bialostockie Centrum Onkologii ( Site 1065), Bialystok
Uniwersyteckie Centrum Kliniczne-Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólnej ( Site, Gdansk
Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku-Oncologii, Chemioterapii ( Site 1064), Słupsk
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1056), Gliwice
Zachodniopomorskie Centrum Onkologii ( Site 1063), Szczecin
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 1054), Kielce
Wilgers Oncology Centre ( Site 1154), Pretoria
Curo Oncology ( Site 1158), Pretoria
LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 1152), Pretoria
Seoul National University Hospital-Oncology ( Site 1600), Seoul
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1601), Seoul
Samsung Medical Center-Division of Hematology/Oncology ( Site 1602), Seoul
Institut Català d'Oncologia - L'Hospitalet ( Site 1202), L'Hospitalet de Llobregat
Länssjukhuset Ryhov-Onkologkliniken ( Site 1253), Jönköping
Karolinska Universitetssjukhuset Solna ( Site 1252), Stockholm
Ankara City Hospital-Medical Oncology ( Site 1357), Çankaya
I.E.U. Medical Point Hastanesi-Oncology ( Site 1360), Izmir, Karsiyaka
Hacettepe Universite Hastaneleri ( Site 1363), Ankara
Liv Hospital Ankara-Oncology ( Site 1353), Ankara
Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 1355), Antalya
Addenbrooke's Hospital ( Site 1400), Cambridge
University College London Hospital ( Site 1405), London
Guy's & St Thomas' NHS Foundation Trust-Oncology & Haematology Clinical Trials ( Site 1401), London
Merck Sharp & Dohme LLC
INDUSTRY